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Abstract
Glioblastoma is a highly aggressive malignant tumor involving glial cells in the human brain. We used high-throughput
sequencing to comprehensively profile the small RNAs expressed in glioblastoma and non-tumor brain tissues. MicroRNAs
(miRNAs) made up the large majority of small RNAs, and we identified over 400 different cellular pre-miRNAs. No known
viral miRNAs were detected in any of the samples analyzed. Cluster analysis revealed several miRNAs that were significantly
down-regulated in glioblastomas, including miR-128, miR-124, miR-7, miR-139, miR-95, and miR-873. Post-transcriptional
editing was observed for several miRNAs, including the miR-376 family, miR-411, miR-381, and miR-379. Using the deep
sequencing information, we designed a lentiviral vector expressing a cell suicide gene, the herpes simplex virus thymidine
kinase (HSV-TK) gene, under the regulation of a miRNA, miR-128, that was found to be enriched in non-tumor brain tissue
yet down-regulated in glioblastomas, Glioblastoma cells transduced with this vector were selectively killed when cultured in
the presence of ganciclovir. Using an in vitro model to recapitulate expression of brain-enriched miRNAs, we demonstrated
that neuronally differentiated SH-SY5Y cells transduced with the miRNA-regulated HSV-TK vector are protected from killing
by expression of endogenous miR-128. Together, these results provide an in-depth analysis of miRNA dysregulation in
glioblastoma and demonstrate the potential utility of these data in the design of miRNA-regulated therapies for the
treatment of brain cancers.
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Introduction
Glioma is an aggressive, malignant brain tumor involving glial
cells. Each year in the United States alone, over 20,000 new
patients are diagnosed with glioma and 13,000 patients die [1].
The most severe and malignant form, glioblastoma multiforme, is
highly infiltrative, rapidly growing, and accounts for 52% of all
brain tumors. Despite advances in chemotherapy, radiation and
surgery, patient prognosis remains poor, with a median survival
time of 14 months [1–3]. Thus, identifying new therapeutic
strategies for glioblastoma by understanding the molecular
pathology of this disease has become a major research focus.
Glioblastoma is associated with a number of mutations at the
genomic level including mutations in the PTEN tumor suppressor
and amplification of the gene encoding the epidermal growth
factor receptor (EGFR) [3,4]. More recently, dysregulated
microRNA (miRNA) expression, such as over-expression of the
anti-apoptotic miRNA miR-21, has been linked to tumor
pathogenesis [5].
MiRNAs are ,22 nt non-coding RNAs that post-transcription-
ally down-regulate cellular gene expression by binding to
complementary sequences generally located in the 39 untranslated
regions (UTRs) of target mRNAs. Target specificity is predom-
inantly determined by nucleotides 2-8 of the mature miRNA, the
miRNA ‘‘seed,’’ which generally exhibits full sequence comple-
mentarity to target mRNAs. Over 1400 human miRNAs have
been identified to date [6], several of which exhibit altered
expression patterns in many human cancers, including glioblasto-
ma, and are thought to positively or negatively regulate cancer
progression [5,7–11]. Post-transcriptional regulation of gene
expression by miRNAs is complex, as a single miRNA species
can regulate multiple mRNAs, while a single mRNA can be
targeted by different miRNAs. In fact, individual miRNAs are
predicted to target as many as 200 different mRNAs [12].
Moreover, single pre-miRNA precursors occasionally give rise to
not only the dominant, miRNA strand, but also a less highly
expressed passenger or star strand, which may also be able to
regulate mRNA expression [13].
Previous miRNA profiling studies, based on miRNA micro-
arrays and PCR arrays, have revealed a number of miRNAs to be
altered in gliomas [9,14–16]. In addition to miR-21 [5], the pro-
oncogenic miRNA miR-10b is upregulated in glioblastomas and
has recently been shown to be a significant contributor to tumor
growth in vivo [9,17]. MiRNAs down-regulated in gliomas include
miR-7, miR-124, miR-128, miR-137, and miR-181a/b
[9,14,15,18,19]. miR-128, miR-124, and miR-137 are all enriched
in the brain and have been shown to regulate neuronal
differentiation, maturation, and/or survival [15,20–23]. Of note,
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amplified at the genetic level and/or over-expressed at the protein
level in gliomas [19].
In this study, we profiled global miRNA expression levels in six
adult glioblastomas and three non-tumor brain tissue samples
using high-throughput sequencing. In contrast to microarrays and
RT-PCR arrays, high-throughput sequencing permits the detec-
tion of not only the dominant mature miRNA species (i.e. 5p
versus 3p) but also potentially important sequence variations that
may occur, such as 59 nucleotide additions, which affect seed-
based targeting, and RNA editing, which alters the targeting
capacity of the mature miRNA [24–27]. Our analysis identified at
least 20 miRNAs and miRNA star strands (miRNA*) that are
significantly differentially expressed. In addition, we identified
variation in the 59 ends of several miRNAs expressed in
glioblastomas as well as editing in the seed region, which should
modulate the mRNA targets bound by these miRNAs. This
information can now be combined with mRNA expression profiles
to identify potential brain-specific target mRNAs.
Our second objective was to use our miRNA deep sequencing
data to facilitate the design of a miRNA-regulated gene therapy
vector. Our aim was to permit the expression of a cell suicide gene,
namely herpes simplex virus thymidine kinase (HSV-TK), in
glioma cells while limiting off-target effects by ablating its
expression in neurons and other important cell types in the brain.
Therefore, we focused on miRNAs that are down-regulated in
glioblastoma compared to non-tumor brain tissue. By exploiting
naturally occurring brain-specific miRNAs, we hypothesized that
the incorporation of specific miRNA target sites into the 39
untranslated region (UTR) of the HSV-TK open reading frame
would effectively restrict its expression in non-transformed cells.
Similar approaches have been used to selectively prevent
transgene expression in hematopoetic cells and other cell types
[28–31]. We engineered artificial target sites for miR-128, which is
highly down-regulated in glioblastoma, into the 39UTR of HSV-
TK. Both the ectopic expression of miR-128 in glioblastoma cells
and the natural, endogenous level of miR-128 expression seen in
neuronal cells indeed limited cell death when compared to control
glioblastoma cells. These results demonstrate the significant
potential of miRNA-regulated therapies in the treatment of
glioblastoma.
Results
Small RNA deep sequencing reveals differences in human
miRNA expression patterns
Using high-throughput sequencing, we investigated miRNA
expression patterns in six human glioblastomas and three non-
tumor brain tissue samples. Small RNA populations correspond-
ing to 18–25 nt in length were sequenced using an Illumina GAII
analyzer. Between 1.8 and 4.9 million reads were obtained per
sample (Table S1) and the sequence length distributions showed
peaks at ,22–23 nt for each sample, corresponding to the average
length of a mature miRNA (Fig. S1). To first determine the
complete miRNA transcriptome of glioblastomas, we pooled reads
from all six samples and aligned them to all human and viral
miRNAs/miRNA*s present in Sanger miRBase v 16.0. Among
the 16,305,416 mapped reads, 484 mature human miRNAs/
miRNA*s were represented at least 10 times (Table S2).
The most abundant miRNAs in both glioblastomas and non-
tumor brain tissues were members of the let-7 family, which
accounted for ,23% of the total reads (Table S2, S3). miR-21,
miR-9, miR-26a, miR-181a, and miR-125b were also abundantly
detected and, together with let-7 (a-i) family members, made up
.65% of all identified miRNAs (Table S2, S3). No viral miRNAs
were detected in any of the samples analyzed.
To determine differences in miRNA expression patterns in
glioblastomas versus non-tumor brain tissue, we used the
miRNAkey pipeline, implementing the SeqEM option to account
for reads mapping to multiple miRNAs [32]. 449 mature miRNAs
and miRNAs* were identified using a filter of RPKM score .1t o
normalize read counts between different libraries and by
considering only those miRNAs occurring in at least two out of
three non-tumor brain libraries or 50% of the glioblastoma
libraries (Table S4). From this set of 449, 68 miRNAs and
miRNA*s were differentially expressed between non-tumor brain
tissues and glioblastomas (p,0.05, Student’s t test; Table S6).
When we applied the standard FDR-adjusted p-value ,0.05 cut-
off, only nine miRNAs were identified that met the criteria (Table
S5). Given the much broader dynamic range of deep sequencing
compared to finite platforms such as miRNA microarrays or real-
time PCR arrays, we therefore used a FDR cut-off of p,0.1. 21
aberrantly expressed miRNAs met the criteria (Fig. 1, Table S5,
Table S6, Fig. S2).
Significantly up-regulated miRNAs in glioblastoma samples
included miR-10b and miR-93 (Table S6). We also observed high
read counts for miR-21, amongst other miRNAs, in all
glioblastoma samples compared to non-tumor samples, congruent
with previous studies showing that this miRNA is highly up-
regulated in glioblastoma (Table S4) [5,9,14,15]; however, there
was variability in the values for miR-21 across the samples and
thus, the miRNA did not meet the final FDR selection criteria.
17 of the 21 significantly dysregulated miRNAs were down-
regulated in glioblastomas (FDR-adjusted p-value ,0.1, fold
change .3) including miR-124, miR-95, miR-132, miR-139-5p,
miR-7, miR-128, miR-487b, and miR-873 (Fig. 1A, Table S6).
miR-212, miR-218, and miR-379, amongst others, also exhibited
lower read counts in glioblastoma compared to non-tumor brain
tissue (Table S4), but did not meet the final FDR selection criteria.
While the aberrant expression of many of these miRNAs is
consistent with previous profiling studies (Table S6) [9,14–16,33],
deep sequencing analysis further revealed at least four significantly
down-regulated miRNAs (miR-95, miR-543. miR-598, and miR-
873) that were not previously reported to be dysregulated in brain
cancers (Table S6).
Validation of miRNA expression patterns by primer
extension
To validate results from our deep sequencing experiments, we
selected four differentially expressed miRNAs for further analysis:
miR-21, miR-128, miR-124, and miR-132. Primer extension
analysis confirmed enhanced expression of miR-21 (Fig. 2A) and
decreased expression of miR-128, miR-124, and miR-132 (Fig. 2B)
in glioblastomas compared to non-tumor brain tissue samples.
Additionally, we could not detect expression of miR-128, miR-
124, or miR-132 in three glioblastoma cell lines (A172, U373, and
U87).
Variations in 5p and 3p strand dominance
MiRNAs are derived from either the 5p or 3p arm of a ,60 nt
hairpin precursor termed a pre-miRNA. Dicer cleaves the pre-
miRNA hairpin into a ,22 nt dsRNA duplex, and one strand of
the duplex is incorporated into the Argonaute-containing RNA-
induced silencing complex (RISC) to become the mature miRNA.
The passenger strand, termed miRNA*, is then degraded. One
factor influencing strand selection is the thermodynamic stability
of the miRNA duplex termini [34]. In some instances, such as
when the termini of the duplex exhibit similar stabilities, either
Glioblastoma Small Regulatory RNAs
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RISCs that are loaded with a functional miRNA* strand [13].
We detected a number of miRNAs processed from both the 5p
and 3p arms of their respective pre-miRNAs, such as miR-136,
miR-151, miR-140, and miR-330 (Table S2, S3). To determine
whether there were any differences in miRNA strand selection in
glioblastomas versus non-tumor brain tissue, we compared 5p:3p
ratios for those miRNAs falling into this category. In at least 70
instances, we observed a switch in the dominant arm of the pre-
miRNA annotated for a given miRNA in at least one of the nine
samples (data not shown). Notably, three miRNAs exhibited
strand selection preferences dependent on the sample origin. The
3p miRNAs for miR-330 and miR-204 were preferentially
detected in non-tumor brain tissue, while the 5p miRNAs were
preferentially detected in glioblastomas (Table S7; Fig. S3B).
Similarly, miR-30a-5p was enriched in glioblastomas while in non-
tumor brain tissue, miR-30a-5p and miR-30a-3p were expressed
at similar levels (Table S7; Fig. S3B). Such changes may indicate
post-transcriptional processing differences—for instance, the
absence or presence of a factor in glial versus non-glial cells that
perturbs miRNA strand selection.
miRNA editing and miRNA sequence variants in the brain
MiRNA dysregulation can occur at many levels. Genomic
mutations in miRNA loci may affect expression and/or processing,
while epigenetic silencing, chromatin modifications, and/or
altered levels of transcription factors may affect expression of the
primary miRNA transcript. Additionally, single nucleotide chang-
es have been shown to affect miRNA expression, processing, and/
or function [35]. One post-transcriptional miRNA modification is
enzymatic editing of the dsRNA primary miRNA transcript by
ADAR (adenosine deaminase acting on RNA) which results in the
conversion of an adenosine (A) to an inosine (I) [24]. A to I
conversions can influence loading of miRNAs into RISC [34] and
Figure 1. Differentially expressed miRNAs in glioblastomas versus non-tumor brain tissue. miRNA expression levels were determined by
deep sequencing. Shown are heat maps for the 38 miRNAs most significantly down-regulated (A) and the 18 miRNAs most significantly up-regulated
(B) in the six glioblastoma (G) samples compared to non-tumor brain tissue (N) (mean fold change .4, p,0.05 by t test). Highlighted are miRNAs that
fulfill the FDR-adjusted selection criteria (** p,0.1) as reported in Table S6. Two additional miRNAs, miR-let-7d and miR-598, also meet the FDR cut-off
but exhibit a fold change ,4 and are not shown. Prior to hierarchical clustering, deep sequencing reads with RPKM values .1 as determined by
miRNAkey [32] were log-transformed, and standardized across all samples to a mean of 0 and standard deviation of 1. Clustering was performed
using Pearson’s correlation (average linkage method) as the distance matrix.
doi:10.1371/journal.pone.0024248.g001
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editing occurs within the miRNA seed region [24,25]. A single A
to I conversion in the seed of miR-376a-5p, for example, redirects
the edited miRNA to a new set of mRNA targets [25]. In deep
sequencing libraries, this conversion is marked by the substitution
of A with G.
To determine whether any miRNAs were post-transcriptionally
edited, we examined miRNA seed sequences (nt 2–7) for A to G
substitutions. Congruent with previous studies, A to G changes
occurred in .60% of the reads for members of the miR-376
family (miR-376a, b, and c) at nucleotide position six of the mature
miRNA sequence (Table 1, Fig. S3A) [36]. We also noted A to G
substitutions at nucleotide position four for miR-381 and position
five for miR-411, miR-200b, and miR-379 (Table 1, Fig. S3A). A
to G substitutions also occurred in the seed region of miR-320
family members; however, these miRNAs were unusual in that
several positions (two, three, and four) exhibited nucleotide
substitutions (Fig. S3A and data not shown). A to G substitutions
for each of the miRNAs were found in both the glioblastoma and
non-tumor brain tissue libraries, and there were no significant
differences in the averaged abundance of edited miRNAs between
the two sample types (Table 1). Furthermore, several of these
miRNA variants (miR-376 family members, miR-411, miR-379,
and miR-320a) have previously been described in deep sequencing
studies performed on human brain [36,37], and therefore, are not
specific to glioblastoma.
MiRNA sequence variations can also arise due to processing
differences at the 59 and 39 ends. While 39 end heterogeneity is
commonly observed for miRNAs, 59 end variations are less
common and can have dramatic consequences on miRNA
targeting since a single 59 nucleotide addition or truncation alters
the sequence of the miRNA seed [27]. To determine whether 59
end variations in miRNA sequences might be associated with the
aberrant expression of specific miRNAs, we examined the major
sequence variants for all identified miRNAs.
We identified 29 miRNAs that exhibited 59 nucleotide
truncations or additions in at least 10% of the mapped reads
(Table S8). Several of the miRNAs down-regulated in glioblasto-
ma (including miR-124-3p and miR-323-3p) exhibited 59
truncations or additions while one up-regulated miRNA, miR-
10b-5p, exhibited 59 variations (Table S8). These 59 nucleotide
variations were observed in all nine sequencing libraries, and with
Figure 2. MiRNA expression in brain tissue samples and glioblastoma cell lines. A. miR-21 expression detected by primer extension. B. miR-
128, miR-124, and miR-132 expression levels detected by primer extension. N = non-tumor brain tissue. G = glioblastoma. A172, U373, and U87 are
glioblastoma cell lines. 6 mg total RNA were used for each reaction. Free probe is shown as a negative control for each miRNA assayed. Primer
extension reactions were resolved on 15% TBE-Urea polyacrylamide gels and exposed to film for either 1 hr (miR-21) or overnight (miR-128, miR-124,
miR-132).
doi:10.1371/journal.pone.0024248.g002
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variability and miRNA expression differences in tumors versus
non-tumor samples (Table S4, S7, and S8). We did, however,
observe major differences in the dominant isoform for at least six
miRNAs when comparing glioblastomas versus non-tumor
samples (Table S7). Interestingly, the dominant form of miR-
324-3p was consistent with the miRNA sequence reported in
miRBase; however, in non-tumor brain, we observed a significant
number of reads mapping to a miR-324-3p isoform that was two
nucleotides longer at the 59 end (Table S7). miR-324, together
with four other miRNAs that show isoform differences in tumor
versus non-tumor samples (miR-106b, miR-335, and miR-411),
also exhibited variations in the major arm of the pre-miRNA
expressed as a miRNA (Table S2, S3, S4, S6). In fact, one third of
the miRNAs with 59 end polymorphisms showed variations in
strand selection preference (Table S4, S6, and data not shown).
Two miRNAs worth noting are miR-30a and miR-330. Two
major isoforms were observed for both miR-30a-3p and miR-330-
3p. 59 end variations occurred at the same frequency in
glioblastomas and non-tumor brain samples for both these
miRNAs (Table S7); however, in the majority of the glioblastoma
libraries, the miRNAs expressed from the 3p arms were under-
represented while miR-30a-5p and miR-330-5p were enriched
(Fig. S3B). These data suggest that 59 end polymorphisms can
reflect fluctuations in strand dominance and presumably, reflect
variations in Drosha processing of the primary miRNA transcript.
miRNAs as potential therapeutic tools to regulate cell
suicide gene expression
After comprehensively determining which miRNAs are dysreg-
ulated in glioblastoma, our next objective was to use this
information in the practical design of a miRNA-regulated gene
therapy vector expressing a cell suicide gene, namely, herpes
simplex virus 1 thymidine kinase (HSV-TK). Cells expressing
HSV-TK selectively undergo apoptosis when cultured in the
presence of the deoxyguanosine analogue ganciclovir (GCV) [38].
HSV-TK-based lentiviral vectors are currently in phase I/II
clinical trials for glioblastoma treatment [39,40]. While lentiviral
vectors are ideal gene therapy tools as they can be pseudotyped to
enter a variety of cell types, one major drawback in glioblastoma
treatment is that such vectors can also enter the tissue surrounding
the tumor, killing otherwise healthy cells, which could have dire
consequences in the brain. We hypothesized that incorporation of
artificial miRNA target sites into the HSV-TK 39UTR could be
an effective means of restricting cell suicide gene expression to
tumor cells.
miR-128 is one of the most significantly and consistently down-
regulated miRNAs in glioblastomas and glioblastoma cell lines
according to data presented here (Fig. 1) as well as previous studies
[9,14,15,31]. Our sequencing data reveal that miR-128 has an
invariant sequence and does not exhibit post-transcriptional
editing or significant 59 end variation. Additionally, miR-128 is
highly enriched in the brain as it is expressed by neurons and is
induced during neuronal differentiation of embryonal carcinoma
(EC) cells [20,21], thus making it an ideal candidate to limit cell
suicide gene expression. We engineered two miR-128 target sites
into the HSV-TK 39UTR (HSV-TK-128.2X) and then transiently
expressed the cell suicide gene in glioblastoma cell lines.
A172 and U373 glioblastoma cells were transfected with
pcDNA3-HSV-TK-128.2X and cultured in media containing
GCV. To determine the lowest effective dose for GCV selection,
cells were plated at 2610
4 cells per well in 24-well plates and
incubated for eight days in media containing various concentra-
tions of GCV (0, 0.1, 1, 10, 100, and 1000 mg/ml) (Fig. S5). A dose
of 10 mg/ml GCV was chosen for subsequent transfection
experiments (Fig. 3, S5B & C).
To specifically demonstrate miRNA regulation of HSV-TK-
128.2X, we cloned a ,250 nt DNA fragment of the region
encompassing pre-miR-128-1 into pcDNA3. miR-128 expression
was confirmed from this vector using luciferase indicator assays
(Fig. S4). Next, U373 cells, which do not express detectable levels
of miR-128 (Fig. 2, 5), were co-transfected with pcDNA3-HSV-
TK-128.2X and the miR-128 expression vector. Ectopic expres-
sion of miR-128 in glioblastoma cells inhibited HSV-TK-128.2X-
mediated cell death when cells were cultured in the presence of
GCV as shown by trypan blue exclusion (Fig. S4), crystal violet
staining, and MTT viability assays (Fig. 3). In contrast, miR-128
did not rescue the viability of U373 cells transfected with an
analogous HSV-TK vector lacking the miR-128 binding sites
(Fig. 3). Interestingly, the growth and viability of both A172 and
U373 cells was not significantly affected by the overexpression of
miR-128 (Fig. 3B, S5), contrary to previous studies using other
glioma cell types that may retain more stem-cell like characteristics
[14,41].
Endogenous miR-128 protects neuronal cells from HSV-
TK induced cell death
We next tested miRNA regulation of HSV-TK-128.2X in cell
lines stably expressing HSV-TK. 293T, U373, and A172 cells
were transduced with pLCE (GFP), pLC-HSV-TK, or pLC-HSV-
TK-128.2X and then transfected with a miR-128 expression
plasmid or empty vector as indicated (Fig. 4). HSV-TK-mediated
killing was unaffected by the presence of the miR-128 target sites
in the absence of miR-128 (Fig. 4A, S5B). Additionally,
overexpression of miR-128 did not affect HSV-TK-mediated
killing in the absence of miR-128 target sites (Fig. 4B & C). We
tested A172 cells with increasing concentrations of GCV. At the
highest dose, 200 mg/mL GCV, ,70% of HSV-TK-expressing
cells were killed (Fig. 4C & D). Similar to Fig. 3, introduction of a
miR-128 expression plasmid rescued both U373 and A172 cells
from cell death when the miR-128 binding sites were present in
the HSV-TK 39UTR (Fig. 4B–D).
Finally, to determine whether endogenous brain-specific
miRNAs could protect cells from a miRNA-regulated cell suicide
gene, we tested the human neuroblastoma cell line, SH-SY5Y.
When cultured in the presence of all-trans retinoic acid (ATRA),
SH-SY5Y cells undergo morphological changes, differentiate into
neuron-like cells, express neuronal markers, and up-regulate a
Table 1. A to G substitutions in miRNA seed sequences.
Average % Edited
miRNA NB GBM Sequence
miR-376b 92% 91% AUCAUAGAGGAAAAUCCAUGU
miR-376c 63% 73% AACAUAGAGGAAAUUCCACGU
miR-376a 62% 69% AUCAUAGAGGAAAAUCCACGU
miR-381 30% 38% UAUACAAGGGCAAGCUCUCUGU
miR-411-5p 21% 20% UAGUAGACCGUAUAGCGUACG
miR-200b 12% 7.3% UAAUACUGCCUGGUAAUGAUGAC
miR-379 7.5% 5.2% UGGUAGACUAUGGAACGUAGG
No significant differences were observed in the occurrence of A to I editing in
glioblastoma (GBM) versus non-tumor brain (NB) samples. Edited ‘‘A’’s are in
bold.
doi:10.1371/journal.pone.0024248.t001
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neuroblastoma cell lines with 10 mM ATRA for five days and
assayed cellular miRNA expression by primer extension (Fig. 5A).
Three glioblastoma cell lines were also treated with ATRA as
controls. Congruent with previous studies [42,43], ATRA
treatment of SH-SY5Y cells induced expression of the brain-
enriched miRNAs miR-128 and miR-124 (Fig. 5A) as well as miR-
132 and miR-7 (not shown).
SH-SY5Y cells were then transduced with pLCE (GFP), pLC-
HSV-TK, or pLC-HSV-TK-128.2X and cultured in media with
or without GCV (Fig. 5B). HSV-TK-mediated killing of
undifferentiated SH-SY5Y cells was again unaffected by the
presence of the miR-128 binding sites. However, when SH-SY5Y
cells were chemically induced to undergo neuronal differentiation,
cells transduced with HSV-TK-128.2X were protected from cell
death as assayed by MTT and crystal violet staining (Fig. 5C and
D). Thus, the expression of endogenous, brain-enriched miR-128
can restrict the effects of a cell suicide gene containing cognate
miRNA binding sites.
Discussion
Here, we present a comprehensive overview of the repertoire of
miRNAs expressed in glioblastoma samples, and we identify
several miRNAs that are dysregulated in glioblastoma. Addition-
ally, we report a number of miRNA sequence variants that are
expressed in the brain. MiRNA regulation of gene expression is an
important aspect of tumorigenesis and cancer progression, and
gaining a better understanding of the miRNAs that are
dysregulated in brain cancers therefore has the potential to reveal
mechanistic insights into the transformed state as well as open the
door to new treatment modalities.
Our findings from deep sequencing of brain tissue and tumor
samples significantly add to the list of miRNAs that are aberrantly
expressed in brain tumors. We identified several new miRNAs that
were not previously reported to be dysregulated in glioblastomas,
including miR-95, miR-543, miR-598, and miR-873 (Fig. 1, Table
S6). Consistent with other glioma miRNA profiling studies
[9,14,15,31], we also observed down-regulation of miR-124,
miR-128, miR-132, and miR-7, and up-regulation of miR-10b,
amongst others, demonstrating that high-throughput sequencing
can be an effective method for profiling miRNA expression.
Compared to microarray and PCR-based profiling platforms,
which detect a pre-determined set of miRNAs, high-throughput
sequencing provides a more complete picture of the miRNAs
expressed in a given sample and is not restricted in the number of
individual miRNAs that can be detected. While these advantages
of high-throughput sequencing allow for a greater dynamic
profiling range, the method is not without limits. Using the
standard FDR selection criterium of p,0.05, only nine miRNAs
were identified here as significantly dysregulated in glioblastoma
samples compared to non-tumor brain tissue (Table S5). Based on
the read counts for individual miRNAs in Tables S2, S3, and S4,
previous profiling studies (listed in Table S6), and data shown here
regarding miRNAs such as miR-21 and miR-128 (Fig. 2, Fig. 5)
that do not meet the standard FDR-adjusted p,0.05 criteria
(Table S5), clearly additional miRNAs identified here are
dysregulated in glioblastoma (Fig. 1, Tables S4 and S6). We
therefore expanded our cut-off to p,0.1 to include 21 significantly
dysregulated miRNAs, 17 of which were down-regulated in
glioblastoma.
Importantly, high-throughput sequencing allowed us to analyze
sequence variations in the detected miRNAs and investigate the
possible presence of exogenous miRNAs such as viral miRNAs. In
this study, we observed significant levels of A to I editing for seven
cellular miRNAs expressed in the brain and 59 end polymorphisms
for at least 30 miRNAs, which could have dramatic consequences
on mRNA targeting [25,27]. In particular, 59 end sequence
heterogeneity may have functional implications as there are
observable differences in the dominant isoforms for a few miRNAs
(miR-335, miR-106b, miR-324) expressed in glioblastomas.
One question we were able to address by deep sequencing was
whether any viral miRNAs might be expressed in the tumors and
perhaps, might play a role in pathogenesis. Human cytomegalo-
virus (HCMV) and other neurotropic viruses, such as the
polyomavirus JC virus (JCV), which replicates in glial cells, have
recently been implicated in gliomas, tumors of the central nervous
system, and other brain cancers [44–49]. Although it is unclear at
this point whether these viruses have any specific role in
tumorigenesis, the incidence of HCMV infection in patients with
 
Figure 3. MiRNA regulation of HSV-TK in U373 glioblastoma
cells. A. Crystal violet staining of U373 glioblastoma cells expressing
HSV-TK or HSV-TK-128.2X following GCV treatment. pcDNA3-HSV-TK-
128.2X contains two perfect binding sites for miR-128 in the 39UTR of
HSV-TK. Cells were co-transfected with either pcDNA3 (+vector) or
pcDNA3-miR-128 (+miR-128) and subjected to 10 mg/mL ganciclovir
selection (+GCV) for 10 days prior to staining. B. miR-128 rescues HSV-
TK-128.2X expressing U373 cells from GCV-induced cell death. U373
cells were co-transfected with pcDNA3 (vector), pcDNA3-HSV-TK, or
pcDNA3-HSV-TK-128.2X and either pcDNA3 as control or pcDNA3-miR-
128 (+miR-128). Cells were plated in 24-well plates with media
containing 10 mg/ml GCV and cell viability was measured at 10 days
by MTT assay as described in Methods (n=3). Absorbance values are
normalized to control cells (transfected with empty vector and grown in
media without GCV).
doi:10.1371/journal.pone.0024248.g003
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have been detected in over 80% of glioblastomas [46,47]. Both
HCMV and JCV are known to express high levels of viral
miRNAs during infection [50]. Therefore, we aligned sequencing
reads from all samples to known viral miRNAs present in
miRBASE v 16.0 as well as the genomes of human a-, b- and
c-herpesviruses (HSV-1, HSV-2, HCMV, HHV-6A/B, HHV-7,
EBV, KSHV) and neurotropic polyomaviruses (JCV and SV40).
No viral small RNAs were detected in any of the nine samples
analyzed (data not shown), indicating that viral miRNAs are likely
not a contributing factor to the development or progression of
glioblastoma.
It is hypothesized that glioblastomas, like other cancers such as
leukemia [51], arise and are maintained by a population of
progenitor cells with stem-like characteristics including the ability
to self-renew for unlimited proliferation [21,52,53]. Indeed, the
glioblastoma miRNA signature supports this hypothesis. Brain-
enriched miR-124 and miR-7, for example, show poor expression
in neural progenitors, but are highly expressed in neurons and
have been implicated in neural differentiation [20,23,54].
Similarly, CREB-induced miR-132 and miR-212, which share
seed sequence homology, promote dendritic outgrowth from
newborn neurons [55] and can target methyl CpG binding protein
2 (MeCP2), a regulator of neuroplasticity [56,57]. Finally, miR-
128, which is also abundantly expressed in neurons, has been
shown to target the Bmi-1 stem cell renewal factor [14]. miR-7,
miR-124, miR-128, miR-132, and miR-212 are amongst the most
highly down-regulated miRNAs found in glioblastomas compared
to non-transformed cells (Fig. 1, Table S4, S6). Furthermore, miR-
7, miR-124, and miR-128 have been reported to impair cell
growth and proliferation when over-expressed in glioma-derived
stem cells [14,15,19,41].
At least 20 cellular miRNAs were differentially expressed in the
six glioblastomas assayed here compared to non-tumor brain
tissue, many of which (miR-128, miR-124, miR-7, miR-132, miR-
139) are consistently dysregulated in not only gliomas but also
other brain cancers including medulloblastomas and neuroblasto-
mas [33]. It is conceivable that several of the down-regulated
miRNAs with no defined functions at this point (i.e., miR-873,
miR-95, miR-543) may exhibit tumor suppressor activity and
normally target components of key signaling pathways that
promote and maintain the growth and survival of glioma cells as
has recently been reported for miR-10b [17].
While elucidating the roles of miRNAs in tumor formation and
progression is certainly an important area of research, we took a
different approach here and used our miRNA profiling data to
explore the possible use of miRNAs in regulating cell suicide gene














Figure 4. MiRNA regulation of HSV-TK in transduced glioblastoma cell lines. A. miR-128 binding sites have no effect on HSV-TK-mediated
killing in cells lacking miR-128. 293T cells were transduced with pLCE (GFP), pL-HSV-TK, or pL-HSV-TK-128.2X and cultured for two weeks in the
presence of 40 mg/ml GCV (n=2). Cell viability was measured by MTT assay. B. miR-128 rescues glioblastoma cells from killing by HSV-TK-128.2X.
U373 cells were transduced with indicated vectors in 6-well plates. 24 hrs post-transduction, cells were transfected with pcDNA3 or pcDNA3-miR-128
using Lipofectamine 2000. 24 hrs later, cells were plated in 24-well plates and cultured for 2 weeks in 20 mg/ml or 80 mg/ml GCV (n=2). C and D.
Dose-dependent response to GCV. A172 cells were transduced with indicated vectors, then transfected with pcDNA3 (grey lines, circles) or pcDNA3-
miR-128 (black lines, squares). 24 hrs later, cells were plated in 24-well plates and cultured for 2 weeks in the presence of GCV (n=2). Cell viability was
measured by MTT assay (B–D).
doi:10.1371/journal.pone.0024248.g004
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multiple cell types, including lymphoid and myeloid cells, muscle
cells, liver cells, and brain cells [28–31]. One study done with
brain developed an insect baculovirus-based vector expressing
HSV-TK under the regulation of three miRNAs (miR-31, miR-
127, and miR-143) reported to be under-expressed in glioblastoma
cell lines [31]. This vector showed the same therapeutic efficacy in
glioblastoma U87 cells as a control HSV-TK vector lacking
artificial miRNA target sites, but when introduced into human
astrocytes, which express the three selected miRNAs, showed
restricted HSV-TK expression, leading to an increase in cell
viability. In our analysis of primary human glioblastoma tissue
samples and brain tissues, miR-31 was not detectable, miR-143
was down-regulated in only half of the glioblastoma samples
analyzed, and miR-127 exhibited only modest down-regulation in
glioblastomas (Table S4). Instead, we focused on miRNAs that are
consistently down-regulated in glioblastomas [9,14,15] (Fig. 1A,
Table S6), and chose miR-128 as the best candidate to restrict cell
suicide gene expression. While miRNA effects on target mRNAs
are usually modest, using a miRNA such as miR-128, which is
brain-enriched and highly expressed in non-glioma cells, poten-
tially maximizes the efficacy of miRNA regulation. Furthermore,
reduced expression of miR-128 is not specific to just glioblastomas
as this miRNA is also down-regulated in other brain cancers [33].
Using an in vitro model to recapitulate expression of brain-
enriched miRNAs, we demonstrated that differentiated neuronal
SH-SY5Y cells transduced with a miR-128-regulated HSV-TK
lentiviral vector are indeed resistant to killing by GCV due to the
expression of endogenous miR-128.
In conclusion, the data presented here provide a comprehensive
analysis of the miRNA signature in glioblastoma and demonstrate
the potential application of miRNA-regulated genes in the
therapeutic treatment of brain cancers— an approach that could
be readily extended to cancers of other organs.
Materials and Methods
Cell lines and tissue samples
U373MG, A172, and U87MG glioblastoma cell lines were
obtained from the Duke Cell Culture Repository and maintained
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 0.1 mM MEM non-essential
amino acids, 1 mM sodium pyruvate, and antibiotics. 293T cells
were maintained in DMEM supplemented with 10% FBS and
antibiotics. SH-SY5Y and SKNMC neuroblastoma cell lines were
maintained in RPMI 1640 supplemented with 10% FBS and
antibiotics. To induce neuronal miRNA expression, 10 mM all-
trans retinoic acid (ATRA) (Sigma) was added to cells for a
minimum of four days.
Human brain tissue samples were obtained through the Brain
Tumor Center Biorepository of the Preston Robert Tisch Brain
Tumor Center at Duke. De-identified tissues were used for all
studies and the data were analyzed anonymously. Non-tumor
brain tissue samples were taken from the right, temporal lobes of
patients with cortical dysplasia. Table S1 describes the glioblas-
toma samples. All tissue samples were obtained fresh, flash frozen
in Tissue-Tek OCT, and stored at -80uC prior to RNA extraction.
None of the samples were post-mortem.
Deep Sequencing and Bioinformatics
Small RNA libraries were prepared as previously described
[58]. Briefly, RNA was extracted from OCT-embedded tissues
 
Figure 5. Endogenous miRNA regulation of HSV-TK protects cells from ganciclovir-induced cell death. A. Brain-enriched miRNAs, miR-
128 and miR-124, are induced during neuronal differentiation of SH-SY5Y cells. Cells were grown in the presence of 10 mM ATRA for .4 days. 10 mg
total RNA were used for primer extensions to detect miRNA expression. SH-SY5Y and SKNMC are neuroblastoma cell lines. A172, U373, and U87 are
glioblastoma cell lines. B. SH-SY5Y cells were transduced with lentiviral vectors expressing GFP, HSV-TK, or HSV-TK-128.2X, plated in 24-well plates at
1610
4 cells per well, and treated with or without 40 mg/ml GCV for 2 weeks (n=2). C and D. Endogenous miR-128 restricts the activity of HSV-TK-
128.2X. SH-SY5Y cells were transduced as in (B) and plated in 24-well plates at 2.5610
4 cells per well. Cells were cultured in the presence of 10 mM
ATRA to induce neuronal differentiation and 40 mg/ml GCV for two weeks (n=2). Cell viability was measured by MTT assay (C), and crystal violet
staining of SH-SY5Y cells treated with either 20 mg/ml or 40 mg/ml GCV is shown in (D).
doi:10.1371/journal.pone.0024248.g005
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Laboratories, Inc., CA) with a homogenizer for 10 sec. 30 mgo f
total RNA was size-fractionated on 15% TBE-UREA polyacryl-
amide gels. Small RNAs (18–24 nt) were extracted and ligated to
adapter sequences for Illumina sequencing. Each 59 adapter
contained a five nucleotide molecular barcode (Table S3). Samples
were combined and sequenced over four lanes on an Illumina
GA2 sequence analyzer at the Duke IGSP Core Sequencing
Facility.
Sequences (36 nt in length) were obtained in FASTA format.
Raw sequencing reads were trimmed for adapter sequences and
filtered for size (.16 nt) using the FASTX toolkit (http://
hannonlab.cshl.edu/fastx_toolkit). FASTA files containing all
unique sequences for the nine libraries are provided (Supporting
Information files S1, S2, S3, S4, S5, S6, S7, S8, and S9). For
differential expression analysis, sequences were aligned to human
and viral miRNAs/miRNA*s present in miRBASE v 16.0
(allowing 2 mismatches) using the miRNAkey pipeline and the
SeqEM option to enable analysis of reads mapping to multiple
miRNAs [32]. miRNAs with a RPKM scores .1.0 were kept for
further analysis (Table S4). For cluster analysis, RPKM normal-
ized read counts were log-transformed, filtered by t-score
(p,0.05), and standardized across all samples to have the mean
equal to zero and the standard deviation (SD) 61. Clustering of
miRNAs exhibiting mean fold change .4.0 was performed in
Cluster 3.0 using the average linkage method and Pearson’s
correlation and visualized in TreeView [59]. False discovery rate
(FDR)-adjusted p-values were calculated using MicroSoft Excel
and are listed in Table S5 for all detected miRNAs.
To interrogate miRNA sequence variations including A to I
editing, reads were aligned to human pre-miRNAs using NCBI
BLAST with the following parameters (W=15, D=2, p=90). For
editing, reads were also perfectly aligned to in silico A to G
substituted mature miRNA/miRNA* sequences. Reads were
parsed further using scripts from the miRDEEP pipeline [60]
and imported into Microsoft Excel.
Primer Extension to detect mature miRNAs
Primer extensions were performed with 5 mg of total RNA using
the AMV PE kit according to the manufacturer’s protocol
(Promega). Oligonucleotides used for probes are listed (Table S9)
and were end-labeled using c
32P-ATP and T4 polynucleotide
kinase. To detect individual miRNAs, a master mix was prepared
for each probe and divided equally amongst the reactions. Reverse
transcription products were separated on 15% TBE-urea poly-
acrylamide gels and exposed to film.
Plasmid constructs, transfections, and lentiviral
transductions
A ,250 nt region encompassing pre-miR-128-1 was PCR
amplified from human genomic DNA and cloned into pcDNA3
downstream of the CMV promoter using XhoI to XbaI sites. The
miR-128 indicator vector (pcDNA3-GL3-128.2X) contains a
firefly luciferase cassette and two fully complementary binding
sites for miR-128 inserted into the 39UTR using XhoI to XbaI (Fig.
S4). pcDNA3-HSV-TK was generated by amplifying the cell
suicide gene, HSV-TK [61], and cloning into pcDNA3 using
HindIII to EcoRI. pL-CMV-eGFP (pLCE) has been previously
described [62]. To generate pL-HSV-TK, eGFP was replaced
with PCR-amplified HSV-TK NheI to XbaI. Two miR-128 binding
sites were then inserted into the 39UTR XhoI to XbaI.
Oligonucleotides are listed in Table S9.
Glioblastoma cell lines were transfected using Lipofectamine
2000 according to manufacturer’s instructions (Invitrogen). For
packaging lentivirus vectors, 293T cells were plated in 10 cm
plates and co-transfected with 5 mg pL-based vector and 1.25 mg
each pMDL-gpRRE, pRSV-REV, and pVSVg [62] using the
calcium phosphate transfection method. Lentivirus was filtered
from the supernatant 48 hrs post-transfection and used for
transductions.
Crystal Violet Staining and MTT assays
Transfections and transductions were carried out in 6-well
plates. 24 hrs post-transfection or post-transduction, cells were
seeded in 24-well plates at 15,000 cells per well, or as indicated,
and placed under ganciclovir (GCV) selection for 10–14 days. SH-
SY5Y cells were seeded in 24-well plates at 25,000 cells per well
48 hrs post-transduction and cultured for 10 days in media
containing GCV and either 10 mM ATRA or 10 mM di-methyl
sulfoxide (DMSO) vehicle control.
For crystal violet staining 10–14 days post-treatment with GCV,
cells were washed twice with phosphate buffered saline (PBS) and
fixed at room temperature for 15 min. in 30% methanol in PBS
containing 0.1% crystal violet. Wells were de-stained with 30%
methanol in PBS lacking crystal violet. To assay cell proliferation
10–14 days post-treatment, cells were washed with PBS and the
media replaced with 1:1 mixture of OptiMEM without phenol red
(Gibco) supplemented with 10% FBS and MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent
(5 mg/ml MTT in PBS) (Invitrogen). Cells were incubated for
2 hrs at 37uC, lysed in buffer (isopropanol containing 0.5% NP40
and 4 mM HCl), and incubated for an additional 2 hrs at 37uC
prior to analysis. Lysates were read in 96-well microtiter plates
using a plate reader (Absorbance =562 nm), and relative cell
growth was determined by comparing absorbance values of
treated cells expressing HSV-TK to absorbance values of control
cells (treated cells transfected with empty vector or expressing
eGFP).
Supporting Information
File S1 Files S1–S9 are FASTA files of deep sequencing reads
for each of the nine samples listed in Table S1. Reads have been



















Table S1 Sequenced brain samples.
(DOC)
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(XLSX)
Table S3 Cortical dysplasia brain miRNA transcrip-
tome.
(XLSX)
Table S4 RPKM scores for nine deep sequencing
libraries.
(XLSX)
Table S5 p-values and False Discovery Rate (FDR)-
adjusted p values for all miRNAs detected in glioblas-
tomas and non-tumor brain tissues.
(XLSX)
Table S6 Differentially expressed miRNAs in glioblas-
tomas (GBM) vs non-tumor brain (NB).
(XLSX)
Table S7 59-end variations and strand dominance in
select miRNAs.
(XLSX)
Table S8 59-end variations alter miRNA seed sequenc-
es.
(XLSX)
Table S9 Oligonucleotides used in this study for deep
sequencing, primer extension, and cloning.
(DOC)
Figure S1 Deep sequencing libraries. A and B. The read
length distributions for each deep sequencing library are shown.
The majority of reads in each library are 22-23 nt in length, which
is the average length of a mature miRNA.
(EPS)
Figure S2 Differentially expressed miRNAs. Scatter-plot
drawn in ‘R’ of mean RPKM scores (miRNA expression values)
for glioblastoma miRNAs (x-axis) compared to non-tumor brain
miRNAs (y-axis). Each point represents a unique miRNA.
Differentially expressed miRNAs (p,0.05) are highlighted in
red. Points that fall above the black line are indicative of miRNAs
that are down-regulated in glioblastomas. The linear regression of
the entire sample set is shown in blue.
(EPS)
Figure S3 Variations in miRNA sequences. A. Post-
transcriptional editing occurs in the seed regions of several brain-
enriched miRNAs. Shown is the average percent of A to I editing in
seed regions (nt 2-7) for individual miRNAs in all nine samples
analyzed. This value was determined by comparing the number of
reads exhibiting A to G substitutions at a specific nucleotide position
for a given miRNA to the number of total reads mapping to the
miRNA. All miRNAs identified across the nine deep sequencing
libraries were interrogated. Each blue dot represents one individual
miRNA, which are ordered based on the amount of editing events (x-
axis). The top nine miRNAs exhibiting significant A to I editing are
highlighted. B. miR-330, miR-30a, and miR-204 show differences in
the 5p:3p ratios in glioblastomas (GBM) compared to non-tumor
brain (NB). p values are reported according to Welch’s t test.
(EPS)
Figure S4 Ectopic expression of miR-128. A. 293T cells
were co-transfected with 1 mg pcDNA3 (vector) or pcDNA3-miR-
128 (miR-128), 50 ng firefly luciferase expression vector, pFLuc-
128.2x containing two miR-128 binding sites or pFLuc-2X
control, and 10 ng renilla luciferase expression vector, pRLuc,
as internal control using Lipofectamine 2000 (Invitrogen). Lysates
were harvested and luciferase activity measured 72 hrs post-
transfection using the dual luciferase assay kit (Promega) (n=3). B.
A172 or U373 glioblastoma cells were transfected as in (A).
Luciferase activity was measured 72 hrs post-transfection (n=3).
pcDNA3-miR-128 inhibits luciferase expression from pFLuc-
128.2X, indicative of miRNA expression. RLU = relative light
units.
(EPS)
Figure S5 A. Dose-dependent response to GCV treatment.
U373 and A172 cells were transfected in 6-well plates with 1 mg
pcDNA3-HSV-TK-128.2X and 1 mg filler DNA (Lipofectamine).
24 hrs post-transfection, cells were plated at 2610
4 cells per well in
24-well plates and treated with indicated concentrations of GCV.
Crystal violet staining was performed 8 days post-GCV. B and C.
U373 cells were co-transfected with 1 mg pcDNA3 (vector),
pcDNA3-HSV-TK (HSV-TK), or pcDNA3-HSV-TK-128.2X
(HSV-TK-128.2X) and 1 mg either pcDNA3 (vector) or
pcDNA3-miR-128 (miR-128). 24 hrs post-transfection, cells were
plated in 24-well plates at 1610
4 cells per well in media containing
10 mg/ml GCV (B) or as indicated (C). Cells were stained 10-12
days post-transfection. D. Cell viability was determined by trypan
blue exclusion. U373 cells were co-transfected with pcDNA3
(vector), pcDNA-HSV-TK, or pcDNA-HSV-TK-128.2X and
either pcDNA3 or pcDNA3-miR-128. 24 hrs post-transfection,
cells were plated at 2610
4 cells per well in 12-well plates and
cultured in the presence of 20 mg/ml GCV (n=2). 10 days post-
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